Illinois court rules in GSK's favour in Zantac case
GSK
1,663.50p
16:55 09/09/24
GSK was upbeat after securing a legal victory in a case in the ongoing litigation surrounding its discontinued heartburn drug Zantac.
FTSE 100
8,270.84
17:14 09/09/24
FTSE 350
4,557.85
16:49 09/09/24
FTSE All-Share
4,513.72
17:14 09/09/24
Pharmaceuticals & Biotechnology
24,027.58
16:49 09/09/24
The FTSE 100 pharmaceuticals giant said a jury in an Illinois state court ruled in its favour, finding it not liable for a plaintiff's colorectal cancer.
It said the verdict aligned with the prevailing scientific consensus, which held that there was no consistent or reliable evidence linking the active ingredient ranitidine to an increased risk of cancer.
The company emphasised that the decision was backed by 16 epidemiological studies that had examined the potential health impacts of ranitidine.
GSK reiterated its commitment to vigorously defending itself against the remaining claims related to the Zantac.
The company also noted that the court had previously dismissed the plaintiff's request for punitive damages, further strengthening GSK's position in the legal battle.
At 0804 BST, shares in GSK were up 0.42% at 1,554p.
Reporting by Josh White for Sharecast.com.